Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients

  • Zekri, Abdel-Rahman N (Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute) ;
  • Bakr, Yasser Mabrouk (Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute) ;
  • Ezzat, Maali Mohamed (Tropical Medicine Department, Faculty of Medicine, Cairo University) ;
  • Zakaria, Mohamed Serag Eldeen (Tropical Medicine Department, Faculty of Medicine, Cairo University) ;
  • Elbaz, Tamer Mahmoud (Tropical Medicine Department, Faculty of Medicine, Cairo University)
  • Published : 2015.11.04


Background: Early detection of various kinds of cancers nowadays is needed including colorectal cancer due to the highly significant effects in improving cancer treatment. The aim of this study was to evaluate the potential value of adiponectin, visfatin and resistin as early biomarkers for colorectal cancer patients. Materials and Methods: Serum levels of adiponectin, visfatin and resistin were measured by a sandwich-enzyme-linked (ELISA) assay technique in 114 serum samples comprising 34 patients with colorectal cancer (CRC), 27 with colonic polyps (CP), 24 with inflammatory bowel disease (IBD) and 29 healthy controls. The diagnostic accuracy of each serum marker was evaluated using receiver-operating characteristic (ROC) curve analysis. Results: The mean concentration of adiponectin was significantly higher in CRC and CP groups than IBD and control groups (P-value <0.05). Also the mean concentration of serum resistin was significantly elevated in the IBD and control groups compared to CRC and CP groups (P-value = 0.014). However, no significant difference was noted in patients of the CRC and CP groups. On the other hand, the mean concentration of visfatin was significantly elevated in CRC and control groups compared to CP and IBD groups (P-value = 0.03). ROC analysis curves for the studied markers revealed that between CRC and IBD groups serum level of adiponectin had a sensitivity of 76.7% and a specificity of 76% at a cut off value of 3940, +LR being 3.2 and -LR 0.31 with AUC 0.852, while serum level of adiponectin between CP and IBD had a sensitivity of 77.8% and a specificity of 75% at a cut off value of 3300, with +LR=3.11 and -LR = 0.3 with AUC 0.852. On the other hand the serum level of visfatin between CRC and CP groups had a sensitivity of 65.5% and a specificity of 66.7 at a cut off value of 2.4, +LR being 1.67 and -LR 0.52 with AUC 0.698. Also the serum level of resistin had a sensitivity of 62.5% and a specificity of 70.3% at a cut off value of 24500, with +LR=2.1 and -LR = 0.53 with AUC 0.685 between control and other groups. On the other hand by comparing control vs CP groups resistin had a sensitivity of 81.8% and a specificity of 70.8% at a cut off value of 17700, with +LR=2.8 and -LR = 0.26 with AUC 0.763 while visfatin had a sensitivity of 68.2% and a specificity of 70.8% at a cut off value of 2.7, with +LR=2.34 and -LR = 0.0.45 with AUC 0.812. Conclusions: These findings support potential roles of adiponectin, visfatin and resistin in early detection of CRC and discrimination of different groups of CRC, CP or IBD patients from normal healthy individuals.


Colorectal carcinoma;irritable bowel disease;colonic polyps;adiponectin;visfatin;resistin


  1. Nakajima TE, Yamada Y, Hamano T, et al (2010). Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci, 101, 1286-91.
  2. Otake S, Takeda H, Fujishima S, et al (2010). Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol, 16, 1252-7.
  3. Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J BC (2005). Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta, 1732, 96-102.
  4. Slomian G, Swietochowska E, Malinowska-Borowska J, et al (2014). Association between chemotherapy and plasma adipokines in patients with colorectal cancer. Pharmacol Reports, 66, 902-7.
  5. Tandon K, Imam M, Ismail BES, Castro F (2015). Body mass index and colon cancer screening: the road ahead. World J Gastroenterol, 21, 1371-6.
  6. Tulubas F, Mete R, Oznur M, Topcu B (2013). The role of adipocytokines in colon cancer and adenomas / uloga adipocitokina u kanceru i adenomima debelog creva. J Med Biochem, 33, 135-42.
  7. Yamaji T, Iwasaki M, Sasazuki S TS (2010). Interaction between adiponectin and leptin Influences the risk of colorectal adenoma. Cancer Res, 70, 5430-7.
  8. Yu LX, Zhou NN, Liu LY, et al (2014). Adiponectin receptor 1 (ADIPOR1) rs1342387 polymorphism and risk of cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 7515-20.
  9. Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P (2006). Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 15, 401-2.
  10. MJ T (2002). Cachexia in cancer patients. Nat Rev Cancer, 2, 862-71.
  11. Stofkova A (2010). Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul, 44, 25-36.
  12. Akdogan R, Ozgur O, Gucuyeter S, et al (2014). A pilot study of Helicobacter pylori genotypes and cytokine gene polymorphisms in reflux oesophagitis and peptic ulcer disease. Bratisl Lek List, 115, 221-8.
  13. Axelsson J, Bergsten A, Qureshi AR, et al (2006). Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int, 69, 596-604.
  14. Ayyildiz T, Dolar E, Ugras N, et al (2015). Adipo-R1 and adipo-R2 expression in colorectal adenomas and carcinomas. Asian Pac J Cancer Prev, 16, 367-72.
  15. Becarevic M, Seferovic J, Ignjatovic S, Singh S M-, N S (2012). Adiponectin non-esterified fatty acids and antiphospholipid antibodies in type II diabetes mellitus. J Med Biochem, 31, 199-204.
  16. Dalamaga M, Karmaniolas K, Panagiotou A, et al (2015). Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control, 20, 193-9.
  17. Dalamaga M, Archondakis S, Sotiropoulos G, et al (2012). Could serum visfatin be a potential biomarker for postmenopausal breast cancer? Maturitas, 71, 301-8.
  18. Erarslan E, Turkay C, Koktener A, et al (2009). Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci, 54, 862-8.
  19. Fazeli MS, Dashti H, Akbarzadeh S, et al (2013). Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine, 62, 81-5.
  20. Gado A, Ebeid B, Abdelmohsen A, Axon A (2013). Colorectal cancer in Egypt is commoner in young people: Is this cause for alarm? Alexandria J Med. Alexandria University Faculty of Medicine
  21. Gan AM, Butoi ED, Manea A, et al (2013). Inflammatory effects of resistin on human smooth muscle cells: up-regulation of fractalkine and its receptor, CX3CR1 expression by TLR4 and Gi-protein pathways. Cell Tissue Res, 351, 161-74.
  22. Garten A, Petzold S, Korner A, Imai SI, Kiess W (2009). Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab, 20, 130-8.
  23. Ghaemmaghami S, Mohaddes SM, Hedayati M, et al (2013). Resistin and visfatin expression in HCT-116 colorectal cancer cell Line. Int J Mol Cell Med, 2, 143-50.
  24. Gonullu G, Kahraman H, Bedir A, Bektas A, Yucel I (2010). Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis, 25, 205-12.
  25. Phelip JM, Bageacu S, Baconnier M (2011). Comparison of adiponectin concentration between pancreatic cancer and colorectal cancer. J Gastrointest Oncol, 2, 232-9.
  26. Joshi RK, Lee SA (2014). Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev, 15, 397-405.
  27. Karmiris K, Koutroubakis IE, Xidakis C, et al (2006). Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis, 12, 100-5.
  28. Kaser S, Kaser A, Sandhofer A, et al (2003). Resistin messenger- RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun, 309, 286-90.
  29. Kralisch S, Klein J, Lossner U, et al (2005). Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol, 185, 1-8.
  30. Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E (2009). Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis, 24, 275-81.
  31. Lee ES, Park SH, Kim MS, et al (2012). Caffeic acid disturbs monocyte adhesion onto cultured endothelial cells stimulated by adipokine resistin. J Agric Food Chem, 60, 2730-9.

Cited by

  1. Alteration of Leptin and Adiponectin in Multistep Colorectal Tumorigenesis vol.17, pp.4, 2016,
  2. Circulating visfatin levels and cancers risk: A systematic review and meta-analysis pp.00219541, 2018,